INTEGRATED NON-CLINICAL AND CLINICAL RISK ASSESSMENT TO OBVIATE THE NEED FOR A DEDICATED QTC STUDY OF IXAZOMIB IN CANCER PATIENTS.

被引：0
|
作者：
Gupta, N. [1 ]
Huh, Y. [2 ]
Hutmacher, M. M. [2 ]
Ottinger, S. [1 ]
Hui, A. [1 ]
Venkatakrishnan, K. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] A2PG, Ann Arbor, MI USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PC-05
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [1] INTEGRATED NON-CLINICAL AND CLINICAL RISK ASSESSMENT TO OBVIATE THE NEED FOR A DEDICATED QTC STUDY OF IXAZOMIB IN CANCER PATIENTS.
    Gupta, N.
    Huh, Y.
    Hutmacher, M. M.
    Ottinger, S.
    Hui, A.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S23 - S23
  • [2] Integrated nonclinical and clinical risk assessment to obviate the need for a dedicated QTc study of ixazomib citrate (MLN9708) in cancer patients (pts)
    Gupta, Neeraj
    Huh, Yeamin
    Hutmacher, Matthew M.
    Ottinger, Sean
    Hui, Ai-Min
    Venkatakrishnan, Karthik
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients
    Gupta, Neeraj
    Huh, Yeamin
    Hutmacher, Matthew M.
    Ottinger, Sean
    Hui, Ai-Min
    Venkatakrishnan, Karthik
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (03) : 507 - 516
  • [4] Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients
    Neeraj Gupta
    Yeamin Huh
    Matthew M. Hutmacher
    Sean Ottinger
    Ai-Min Hui
    Karthik Venkatakrishnan
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 507 - 516
  • [5] Integrated risk assessment and predictive value to humans of non-clinical repolarization assays
    Wallis, Robert M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (01) : 115 - 121
  • [6] Integrated risk assessment and predictive value to humans of non-clinical repolarisation assays
    Wallis, R.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 8 - 8
  • [7] Use of non-clinical and clinical data for the environmental risk assessment of Glybera (alipogene tiparvovec)
    Freidig, A.
    Salmon, F.
    Jenal, U.
    Petry, H.
    HUMAN GENE THERAPY, 2010, 21 (10) : 1401 - 1402
  • [8] Clinical and immunological allergy assessment in cancer patients.
    Muzzi Carvalho Carneiro, Bruno Gustavo
    Petroianu, Andy
    Nogueira Machado, Jose Augusto
    Ferreira dos Anjos, Paula Martins
    da Silva, Fabiana Rocha
    Alberti, Luiz Ronaldo
    Resende, Vivian
    Barrientos, Sofia Candia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] PANGAEA 2.0 EVOLUTION: Clinical and non-clinical parameters in the early assessment of SPMS patients in clinical routine
    Lassek, C.
    Weiss, C.
    Ziemssen, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 326 - 326
  • [10] Review of non-clinical risk models to aid prevention of breast cancer
    Al-Ajmi, Kawthar
    Lophatananon, Artitaya
    Yuille, Martin
    Ollier, William
    Muir, Kenneth R.
    CANCER CAUSES & CONTROL, 2018, 29 (10) : 967 - 986
12345